Cerebral venous sinus thrombosis after COVID-19 vaccination and congenital deficiency of coagulation factors: Is there a correlation?

References

• Han X, Xu P, Ye Q. Analysis of COVID-19 vaccines: types, thoughts, and application. J Clin Lab Anal [Internet]. 2021;35:1. https://pubmed.ncbi.nlm.nih.gov/34396586
   Web of Science ®Google Scholar
• Ravichandran S, Coyle E M, Klenow L, Tang J, Grubbs G, Liu S, Wang T, Golding H, and Khurana S. (2020). Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits. Sci Transl Med, 12(550),– 10.1126/scitranslmed.abc3539
   Web of Science ®Google Scholar
• Mascellino M Teresa, Di Timoteo F, De Angelis M, and Oliva A. (2021). Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. Infect Drug Resist, 14 3459–5. 10.2147/IDR.S315727
   PubMed Web of Science ®Google Scholar
• Sette A, and Crotty S. (2021). Adaptive immunity to SARS-CoV-2 and COVID-19. Cell, 184(4), 861–880. 10.1016/j.cell.2021.01.007
   PubMed Web of Science ®Google Scholar
• Grifoni A et al . (2020). Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell, 181(7), 1489–1501.e15. 10.1016/j.cell.2020.05.015
   PubMed Web of Science ®Google Scholar
• ASL Foggia Vaccinazioni modulistica https://www.sanita.puglia.it/web/asl-foggia/vaccini-modulistica2021
   Google Scholar
• Ferrari E et al . (2020). High Prevalence of Acquired Thrombophilia Without Prognosis Value in Patients With Coronavirus Disease 2019. J Am Heart Assoc, 9(21), e017773 10.1161/JAHA.120.017773
   PubMed Web of Science ®Google Scholar
• Gómez-Mesa J Esteban, Galindo-Coral S, Montes M Claudia, and Muñoz Martin A J. (2021). Thrombosis and Coagulopathy in COVID-19. Curr Probl Cardiol, 46(3), 100742 10.1016/j.cpcardiol.2020.100742
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Klamroth R, Langer F, Albisetti M, von Auer C, Ay C, Korte W, Scharf R E, Pötzsch B, and Greinacher A. (2021). Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH. Hamostaseologie, 41(3), 184–189. 10.1055/a-1469-7481
   PubMedGoogle Scholar
• Cines D B, and Bussel J B. (2021). SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. N Engl J Med, 384(23), 2254–2256. 10.1056/NEJMe2106315
   PubMed Web of Science ®Google Scholar
• Franchini M, Liumbruno G Maria, and Pezzo M. (2021). COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome. Eur J Haematol, 107(2), 173–180. 10.1111/ejh.13665
   PubMed Web of Science ®Google Scholar
• Long B, Bridwell R, and Gottlieb M. (2021). Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines. Am J Emerg Med, 49 58–61. 10.1016/j.ajem.2021.05.054
   PubMed Web of Science ®Google Scholar
• Schultz N H et al . (2021). Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med, 384(22), 2124–2130. 10.1056/NEJMoa2104882
   PubMed Web of Science ®Google Scholar
• Greinacher A, Thiele T, Warkentin T E, Weisser K, Kyrle P A, and Eichinger S. (2021). Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med, 384(22), 2092–2101. 10.1056/NEJMoa2104840
   PubMed Web of Science ®Google Scholar
• Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, Goldblatt D, Kotoucek P, Thomas W, and Lester W. (2021). Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. N Engl J Med, 384(23), 2202–2211. 10.1056/NEJMoa2105385
   PubMed Web of Science ®Google Scholar
• American Society of Hematology Thrombosis with Thrombocytopenia Syndrome (also termed Vaccine-induced Thrombotic Thrombocytopenia http://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia
   Google Scholar
• CDC Advisory Committee on Immunization Practices (ACIP) Thrombosis with thrombocytopenia syndrome (TTS) following Janssen COVID-19 vaccine https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-04-23/03-COVID-Shimabukuro-508.pdf
   Google Scholar
• Borgel D, Gandrille S, and Aiach M. (1997). Protein S deficiency Thrombosis and haemostasis, 78, 351–6.
   PubMed Web of Science ®Google Scholar
• EMA - European Medicines Agency AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood#:~:text=EMA%20confirms%20overall%20benefit%2Drisk,COVID%2D19%20Vaccine%20AstraZeneca
   Google Scholar
• Poort S R, Rosendaal F R, Reitsma P H, and Bertina R M. (1996). A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood, 88(10), 3698–703.
   PubMed Web of Science ®Google Scholar
• Gonzalez J V, Barboza A G, Vazquez F J, and Gándara E. (2016). Prevalence and Geographical Variation of Prothrombin G20210A Mutation in Patients with Cerebral Vein Thrombosis: A Systematic Review and Meta-Analysis. PLoS One, 11(3), e0151607 10.1371/journal.pone.0151607
   PubMed Web of Science ®Google Scholar
• Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, and Mannucci P M. (1998). High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med, 338(25), 1793–7. 10.1056/NEJM199806183382502
   PubMed Web of Science ®Google Scholar
• Voysey M et al . (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, 397(10269), 99–111. 10.1016/S0140-6736(20)32661-1
   PubMed Web of Science ®Google Scholar
• Lopez Bernal J et al . (2021). Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ, 373 n1088 10.1136/bmj.n1088
   PubMed Web of Science ®Google Scholar
• Haas E J et al . (2021). Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet, 397(10287), 1819–1829. 10.1016/S0140-6736(21)00947-8
   PubMed Web of Science ®Google Scholar
• Spyropoulos A C and Weitz J I. (2020). Hospitalized COVID-19 Patients and Venous Thromboembolism. Circulation, 142(2), 129–132. 10.1161/CIRCULATIONAHA.120.048020
   PubMed Web of Science ®Google Scholar
• Thompson M G et al . (2021). Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med, 385(4), 320–329. 10.1056/NEJMoa2107058
   PubMed Web of Science ®Google Scholar
• Driggin E et al . (2020). Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. J Am Coll Cardiol, 75(18), 2352–2371. 10.1016/j.jacc.2020.03.031
   PubMed Web of Science ®Google Scholar
• Andrews N J, Stowe J, Ramsay M Eb, and Miller E. (2022). Risk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2 COVID-19 vaccines: A national cohort study in England. Lancet Reg Health Eur, 13 100260 10.1016/j.lanepe.2021.100260
   PubMedGoogle Scholar
• Torjesen I. (2021). Covid-19: Risk of cerebral blood clots from disease is 10 times that from vaccination, study finds. BMJ, n1005 10.1136/bmj.n1005
   PubMedGoogle Scholar